ROS1 and non-small cell lung carcinoma: Neel et al. have demonstrated that different fusion partners affect the subcellular localization of the ROS1 fusions [26] while Li et al. has described that ROS1+ NSCLC patients with CD74-ROS1 fusion partners are more likely to present with brain metastases and showed a trend toward improved survival in the non-CD74-ROS1 group when they were treated with crizotinib [27], suggesting the possibility that fusion partners may have differential responses to therapy.